Skip to contentR
Relay Therapeutics, Inc.
R
RLAYRelay Therapeutics, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$253.00K$253.00Kderived−55.4% vs Q4 2021 Net Income-$67.50M-$67.50MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Relay Therapeutics, Inc. · CIK 1812364 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$72,851,000N/M Operating Cash Flowderived-$57,079,000N/M Free Cash Flowderived-$59,395,000N/M Margins · derivedOperating margin-28794.9%−16850.8 pt vs Q4 2021
Net margin-26681.0%−14784.0 pt vs Q4 2021
ended Dec 31, 2022 · filed Feb 23, 2023 · 54 d after period end